On October 28, the “2025 Shenzhen Top 500 Enterprises” list, released by the Shenzhen Enterprise Confederation and Shenzhen Entrepreneur Association, was officially announced. Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or “the Group”), was once again made the list with honor, ranking at 166th, by virtue of its steady operational performance, outstanding innovation capabilities, and sustained social contributions. Additionally, Shenzhen Kangzhe was also included in the “2025 Top 100 Most Efficient Enterprises of the Shenzhen Top 500” and the “2025 Top 100 Enterprises with the Highest Social Contributions of the Shenzhen Top 500”.
The five consecutive listings of Shenzhen Kangzhe not only reflect the high recognition of its remarkable operational resilience and vibrant innovation vitality in the complex market environment, but also demonstrate the Group’s continuous improvement in scale efficiency and the accelerated release of its quality growth potential in its advantageous specialty fields. Driven by its three core strategies “Product Innovation, Commercial Model Reform, and International Expansion”, CMS has gradually developed into “an innovation-driven, multinational pharmaceutical company with a fully integrated R&D, manufacturing, and commercialization value chain”.
Looking ahead, the Group will continuously focus on unmet medical needs, promote synergistic growth in business scale and development quality, and enhance the accessibility and affordability of innovative drugs, promoting the quality and sustainable development of the biopharmaceutical industry in Shenzhen and contributing to the realization of Healthy China with solid “CMS strength”.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.